Poland· PL-100485255
Briumvi
A ublituximab product containing ublituximabum, registered in Poland by Neuraxpharm Pharmaceuticals, S.L.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ublituximab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG14 (ublituximab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Ublituximab · ATC L04AG14
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Ublituximabum
- Manufacturer
- Neuraxpharm Pharmaceuticals, S.L.
- Country
- Poland (PL)
- ATC code
- L04AG14
- ATC class
- Ublituximab
- Defined daily dose
- 2.68 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08436027472384
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ublituximab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBRIUMVITG Therapeutics, Inc.
- CzechiaBRIUMVINeuraxpharm Pharmaceuticals, S.L., Barcelona
- SwitzerlandBriumvi
- FinlandBriumviNeuraxpharm Pharmaceuticals S.L.
- United KingdomBriumvi 150mg/6ml concentrate for solution for infusion vialsNeuraxpharm UK Ltd
- IrelandBriumvi 150 mg Concentrate for solution for infusionNeuraxpharm Pharmaceuticals S.L.
- IcelandBriumviNeuraxpharm Pharmaceuticals S.L.
- NetherlandsBriumvi 150 mg concentraat voor oplossing voor infusieNeuraxpharm Pharmaceuticals S.L.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Briumvi
- Liechtenstein · Briumvi
- Norway · Briumvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/67050278-d4e5-4c34-8f2f-66ccee35e074 GET /v1/drugs/67050278-d4e5-4c34-8f2f-66ccee35e074?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "150 mg/6 ml",
"packaging": "08436027472384 ¦ Rpz ¦ EU/1/23/1730/001 ¦ 150609\n1 fiol. 6 ml",
"substance": "Ublituximabum 150 mg/6 ml",
"common_name": "Ublituximabum",
"pl_product_id": "100485255",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ublituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.